Lantern Pharma (LTRN) Accounts Payables (2019 - 2026)

Lantern Pharma (LTRN) has reported Accounts Payables for 8 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables fell 9.89% year-over-year to $4.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.3 million (down 9.89% YoY), and the FY2025 full-year result was $4.4 million, up 6.83% from the prior year.
• Accounts Payables advanced to $4.3 million in Q2 2026 per LTRN's latest filing, from $3.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $5.2 million in Q2 2022 and bottomed at $2.1 million in Q3 2023.
• Historically, Accounts Payables has averaged $3.6 million across 5 years, with a median of $3.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 373.0% in 2022, then tumbled 44.86% in 2023.
• Over 5 years, Accounts Payables stood at $2.7 million in 2022, then retreated by 8.75% to $2.5 million in 2023, then surged by 65.27% to $4.1 million in 2024, then increased by 6.83% to $4.4 million in 2025, then retreated by 3.17% to $4.3 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $4.3 million, $3.7 million, and $4.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.